News
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
BioNxt Solutions Inc. announces completion of the Investigational Medicinal Product Dossier (IMPD) for BNT23001, their proprietary sublingual cladribine oral dissolvable film product for multiple sclerosis. Key regulatory milestone achieved -
-
-
-
-
-
-